Health Canada restricts Allergan’s Esmya
Health Canada has placed restrictions on Allergan’s uterine fibroid treatment Esmya, after discovering a possible link between its use and the risk of a rare but serious liver injury.
Read More
Tag: Esmya
New prescriptions of Gideon Richter’s Esyma on hold
Doctors are not to prescribe Gedeon Richter’s Esmya for uterine fibroids in the UK while European regulators carry out a safety review of the drug.
Read More
Allergan, Gedeon’s fibroid drug hits PhIII targets
Allergan and Gedeon Richter are gearing up to file ulipristal acetate in the US in the second half of this year, in the hope of securing approval for the first oral treatment option for women suffering from uterine fibroids in the country.
Read More
NICE backs non-surgical option for fibroids
Women with uterine fibroids stand to gain routine access to a non-surgical treatment on the National Health Service for the first time, after cost regulators endorsed Gedeon Richter’s once-daily pill Esmya as an option.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
